Guru Sonpavde1, Gregory R Pond2, Jonathan E Rosenberg3, Dean F Bajorin3, Toni K Choueiri4, Andrea Necchi5, Giuseppe Di Lorenzo6, Joaquim Bellmunt4. 1. University of Alabama-Birmingham Comprehensive Cancer Center, Birmingham, Alabama. Electronic address: gsonpavde@uabmc.edu. 2. McMaster University, Hamilton, Ontario, Canada. 3. Memorial Sloan Kettering Cancer Center, New York, New York. 4. Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. 5. Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 6. University Federico II, Naples, Italy.
Abstract
PURPOSE: Prognostic factors in patients receiving salvage systemic therapy for advanced urothelial carcinoma include performance status, liver metastasis, hemoglobin and time since chemotherapy. We investigated the impact of albumin, and neutrophil, lymphocyte and platelet counts. MATERIALS AND METHODS: Patient level data from 10 phase II trials were used. Cox proportional hazards regression was applied to evaluate associations with overall survival. An optimal regression model was constructed using forward stepwise selection and risk groups were defined using the number of adverse factors. Trial was a stratification factor. External validation was done in a separate data set of 5 salvage phase II trials. RESULTS: Discovery data were obtained on 708 patients. After adjustment for the 4 known factors a platelet count of the upper limit of normal or greater and albumin less than the lower limit of normal were significant poor prognostic factors. Only the addition of albumin was externally validated. For 0 or 1, 2 and 3 or greater risk factors median overall survival was 8.9, 6.4 and 4.5 months in 207, 171 and 113 patients in the discovery data set of 491, and 10.6, 10.0 and 7.0 months in 73, 47 and 47 patients, respectively, in the validation data set of 167. By adding albumin the c-index improved from 0.610 to 0.639 in the discovery set and from 0.616 to 0.646 in the validation set. CONCLUSIONS: Albumin was externally validated as a prognostic factor for overall survival after accounting for time from prior chemotherapy, hemoglobin, performance status and liver metastasis status in patients receiving salvage systemic therapy for advanced urothelial carcinoma. The discovery of molecular prognostic factors is a priority to further enhance this new preferred 5-factor clinical prognostic model.
PURPOSE: Prognostic factors in patients receiving salvage systemic therapy for advanced urothelial carcinoma include performance status, liver metastasis, hemoglobin and time since chemotherapy. We investigated the impact of albumin, and neutrophil, lymphocyte and platelet counts. MATERIALS AND METHODS:Patient level data from 10 phase II trials were used. Cox proportional hazards regression was applied to evaluate associations with overall survival. An optimal regression model was constructed using forward stepwise selection and risk groups were defined using the number of adverse factors. Trial was a stratification factor. External validation was done in a separate data set of 5 salvage phase II trials. RESULTS: Discovery data were obtained on 708 patients. After adjustment for the 4 known factors a platelet count of the upper limit of normal or greater and albumin less than the lower limit of normal were significant poor prognostic factors. Only the addition of albumin was externally validated. For 0 or 1, 2 and 3 or greater risk factors median overall survival was 8.9, 6.4 and 4.5 months in 207, 171 and 113 patients in the discovery data set of 491, and 10.6, 10.0 and 7.0 months in 73, 47 and 47 patients, respectively, in the validation data set of 167. By adding albumin the c-index improved from 0.610 to 0.639 in the discovery set and from 0.616 to 0.646 in the validation set. CONCLUSIONS:Albumin was externally validated as a prognostic factor for overall survival after accounting for time from prior chemotherapy, hemoglobin, performance status and liver metastasis status in patients receiving salvage systemic therapy for advanced urothelial carcinoma. The discovery of molecular prognostic factors is a priority to further enhance this new preferred 5-factor clinical prognostic model.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Gregory R Pond; Joaquim Bellmunt; Ronan Fougeray; Toni K Choueiri; Angela Q Qu; Guenter Niegisch; Peter Albers; Giuseppe Di Lorenzo; Yacine Salhi; Matthew D Galsky; Neeraj Agarwal; Andrea Necchi; Guru Sonpavde Journal: Clin Genitourin Cancer Date: 2013-06-22 Impact factor: 2.872
Authors: Donald C McMillan; Joseph E M Crozier; Khalid Canna; Wilson J Angerson; Colin S McArdle Journal: Int J Colorectal Dis Date: 2007-01-24 Impact factor: 2.571
Authors: Daniel Y C Heng; Wanling Xie; Meredith M Regan; Lauren C Harshman; Georg A Bjarnason; Ulka N Vaishampayan; Mary Mackenzie; Lori Wood; Frede Donskov; Min-Han Tan; Sun-Young Rha; Neeraj Agarwal; Christian Kollmannsberger; Brian I Rini; Toni K Choueiri Journal: Lancet Oncol Date: 2013-01-09 Impact factor: 41.316
Authors: Matthew D Galsky; Erin Moshier; Susan Krege; Chia-Chi Lin; Noah Hahn; Thorsten Ecke; Guru Sonpavde; James Godbold; William K Oh; Aristotle Bamias Journal: Cancer Date: 2013-05-29 Impact factor: 6.860
Authors: Toni K Choueiri; Robert W Ross; Susanna Jacobus; Ulka Vaishampayan; Evan Y Yu; David I Quinn; Noah M Hahn; Thomas E Hutson; Guru Sonpavde; Stephanie C Morrissey; Geoffrey C Buckle; William Y Kim; Daniel P Petrylak; Christopher W Ryan; Mario A Eisenberger; Amir Mortazavi; Glenn J Bubley; Mary-Ellen Taplin; Jonathan E Rosenberg; Philip W Kantoff Journal: J Clin Oncol Date: 2011-12-19 Impact factor: 44.544
Authors: S Culine; C Theodore; M De Santis; B Bui; T Demkow; J Lorenz; F Rolland; F-M Delgado; B Longerey; N James Journal: Br J Cancer Date: 2006-05-22 Impact factor: 7.640
Authors: Guru Sonpavde; Juliane Manitz; Chen Gao; Darren Tayama; Constanze Kaiser; Daniel Hennessy; Doris Makari; Ashok Gupta; Shaad Essa Abdullah; Guenter Niegisch; Jonathan E Rosenberg; Dean F Bajorin; Petros Grivas; Andrea B Apolo; Robert Dreicer; Noah M Hahn; Matthew D Galsky; Andrea Necchi; Sandy Srinivas; Thomas Powles; Toni K Choueiri; Gregory R Pond Journal: J Urol Date: 2020-06-18 Impact factor: 7.450
Authors: Andrea Necchi; Salvatore Lo Vullo; Luigi Mariani; Daniele Raggi; Patrizia Giannatempo; Giuseppina Calareso; Elena Togliardi; Flavio Crippa; Nicola Di Genova; Federica Perrone; Maurizio Colecchia; Biagio Paolini; Giuseppe Pelosi; Nicola Nicolai; Giuseppe Procopio; Roberto Salvioni; Filippo G De Braud Journal: Invest New Drugs Date: 2016-02-12 Impact factor: 3.850
Authors: Jacqueline T Brown; Yuan Liu; Julie M Shabto; Dylan J Martini; Deepak Ravindranathan; Emilie Elise Hitron; Greta Anne Russler; Sarah Caulfield; Lauren Beth Yantorni; Shreyas S Joshi; Haydn Kissick; Kenneth Ogan; Wayne B Harris; Bradley C Carthon; Omer Kucuk; Viraj A Master; Mehmet Asim Bilen Journal: Oncologist Date: 2021-03-18
Authors: Dylan J Martini; Julie M Shabto; Subir Goyal; Yuan Liu; T Anders Olsen; Sean T Evans; Benjamin L Magod; Deepak Ravindranathan; Jacqueline T Brown; Lauren Yantorni; Greta Anne Russler; Sarah Caulfield; Jamie M Goldman; Bassel Nazha; Shreyas Subhash Joshi; Haydn T Kissick; Kenneth E Ogan; Wayne B Harris; Omer Kucuk; Bradley C Carthon; Viraj A Master; Mehmet Asim Bilen Journal: Oncologist Date: 2021-08-18
Authors: Ivan de Kouchkovsky; Li Zhang; Errol J Philip; Francis Wright; Daniel M Kim; Divya Natesan; Daniel Kwon; Hansen Ho; Son Ho; Emily Chan; Sima P Porten; Anthony C Wong; Arpita Desai; Franklin W Huang; Jonathan Chou; David Y Oh; Raj S Pruthi; Lawrence Fong; Eric J Small; Terence W Friedlander; Vadim S Koshkin Journal: J Immunother Cancer Date: 2021-05 Impact factor: 13.751
Authors: Risa L Wong; Lorin A Ferris; Olivia A Do; Sarah K Holt; Jorge D Ramos; Simon J Crabb; Cora N Sternberg; Joaquim Bellmunt; Sylvain Ladoire; Ugo De Giorgi; Lauren C Harshman; Ulka N Vaishampayan; Andrea Necchi; Sandy Srinivas; Sumanta K Pal; Guenter Niegisch; Tanya B Dorff; Matthew D Galsky; Evan Y Yu Journal: Oncologist Date: 2021-08-17